Clinical and functional course of patients with cystic fibrosis treated with lumacaftor/ivacaftor at a children’s hospital. A case series
Archivos Argentinos de Pediatria · 2023
DOI: 10.5546/aap.2022-02825.eng ↗Kurz gefasst
Fallbericht in der Zeitschrift Archivos Argentinos de Pediatria, 2023. Verfasst von M Sol Fernández Sardá und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pulmonology, Hospital de Pediatría S.A.M.I.C. Prof. Dr. Juan P. Garrahan, City of Buenos Aires, Argentina. Hauptthemen laut MEDLINE: Cystic Fibrosis.
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
Cystic fibrosis transmembrane regulator (CFTR) modulators treat defective CFTR protein. Our objective is to describe the course of children with cystic fibrosis treated with lumacaftor/ivacaftor. This is a case series of 13 patients aged 6 to 18 years with ≥ 6 months of treatment. Forced expiratory volume in the first second (FEV1), body mass index (BMI) Z-score, antibiotic therapy/year, before treatment and for 24 months after treatment were analyzed. At 12 months (9/13) and 24 months (5/13), the median change in the percent predicted FEV1 (ppFEV1) was 0.5 pp (-2-12) and 15 pp (8.7-15.2) and the BMI Z-score was 0.32 points (-0.2-0.5) and 1.23 points (0.3-1.6). In the first year, in 11/13 patients, the median number of days of antibiotic use decreased from 57 to 28 (oral) and from 27 to 0 (intravenous). Two children had associated adverse events. Los moduladores de la proteína reguladora transmembrana de fibrosis quística (CFTR) tratan el defecto de esta proteína. El objetivo es describir la evolución de niños con fibrosis quística tratados con lumacaftor/ivacaftor. Se trata de una serie de 13 pacientes de 6 a 18 años con ≥ 6 meses de tratamiento. Se analizaron el volumen espiratorio forzado en el primer segundo (VEF1), puntaje Z del índice de masa corporal (IMC), antibioticoterapia/año, antes del tratamiento y durante 24 meses posteriores. A los 12 meses (9/13) y 24 meses (5/13), la mediana de cambio del porcentaje del predicho VEF1 (ppVEF1) fue de 0,5 pp [-2-12] y 15 pp [8,7-15,2], y del puntaje Z de IMC de 0,32 puntos [-0,2-0,5] y 1,23 puntos [0,3-1,6]. El primer año (11/13) la mediana de días de uso de antibiótico disminuyó de 57 a 28 (oral) y de 27 a 0 (intravenoso). Dos niños evidenciaron eventos adversos asociados.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pulmonology, Hospital de Pediatría S.A.M.I.C. Prof. Dr. Juan P. Garrahan, City of Buenos Aires, Argentina.
ORCID-Profile: M Sol Fernández Sardá, Lourdes Báez Mellid, Paula Brizuela, Manuela Dicembrino, Hilda Giugno, Claudio Castaños
Zitieren
APA
Fernández Sardá, M. S., Báez Mellid, L., Brizuela, P., Dicembrino, M., Giugno, H., & Castaños, C. (2023). Clinical and functional course of patients with cystic fibrosis treated with lumacaftor/ivacaftor at a children’s hospital. A case series. Archivos Argentinos de Pediatria. https://doi.org/10.5546/aap.2022-02825.eng
Vancouver
Fernández Sardá MS, Báez Mellid L, Brizuela P, Dicembrino M, Giugno H, Castaños C. Clinical and functional course of patients with cystic fibrosis treated with lumacaftor/ivacaftor at a children’s hospital. A case series. Archivos Argentinos de Pediatria. 2023. doi:10.5546/aap.2022-02825.eng
BibTeX
@article{FernndezSard2023,
author = {Fernández Sardá, M Sol and Báez Mellid, Lourdes and Brizuela, Paula and Dicembrino, Manuela and Giugno, Hilda and Castaños, Claudio},
title = {Clinical and functional course of patients with cystic fibrosis treated with lumacaftor/ivacaftor at a children’s hospital. A case series},
journal = {Archivos Argentinos de Pediatria},
year = {2023},
doi = {10.5546/aap.2022-02825.eng}
}
EUVIMED